15(R)-Lipoxin A4

Lipid-derived lipoxins are produced at the site of vascular and mucosal inflammation where they down-regulate polymorphonuclear leukocyte recruitment and function. 15(R)-Lipoxin A4 (15(R)-LXA4) is derived from the aspirin-triggered formation of 15(R)-HETE (Cay-34710) from arachidonic acid (Cay-90010). 15(R)-LXA4 inhibits LTB4-induced chemotaxis, adherence, and transmigration of neutrophils with twice the potency of LXA4 (Cay-90410) demonstrating activity in the nM range. The anti-inflammatory effects of aspirin may be ascribed in part to the ability of 15(R)-LXA4 to regulate leukocyte function. 15(R)-LXA4 is reported to promote resolution of inflammation in LPS-treated stromal cells derived from intermediate-stage diseased supraspinatus tendons as evidenced by increased expression of the STAT-6 pathway target genes, ALOX15 and CD206.Formal Name: 5(S),6(R),15(R)-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid. CAS Number: 171030-11-8. Synonyms: AT-Lipoxin A4, 15-epi Lipoxin A4, 15(R)-LXA4. Molecular Formula: C20H32O5. Formula Weight: 352.5. Purity: >95%. Formulation: (Request formulation change), A solution in ethanol. Solubility: DMF: 50 mg/ml, Ethanol: 50 mg/ml, PBS (pH 7.2): 1 mg/ml. lambdamax: 302 nm. SMILES: CCCCC[C@@H](O)\C=C/C=C/C=C\C=C/[C@@H](O)C(O)CCCC(=O)O. InChi Code: InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18-,19+/m1/s1. InChi Key: IXAQOQZEOGMIQS-JEWNPAEBSA-N.